http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Partha Sarathi Choudhury (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Manoj Gupta,Partha Sarathi Choudhury,Sudhir Rawal,G. Karthikeyan,Vineet Talwar,Kumar Deep Dutta,Amitabh Singh 대한핵의학회 2019 핵의학 분자영상 Vol.53 No.6
Purpose The aimof this study was to evaluate safety and therapeutic efficacy of lutetium 177 prostate-specific membrane antigen (Lu-177-PSMA) in metastatic castration-resistant prostate cancer (mCRPC) patients with low performance status. Methods Twenty-two patients already treated with anti-androgens and docetaxel were enrolled for one cycle of Lu-177-PSMA therapy. Haemoglobin, total leukocyte counts, platelets and serum creatinine for toxicity profile while prostate specific antigen (PSA), Eastern Cooperative Oncology Group (ECOG) performance status, visual analogue scale (VAS) and analgesic quantification scale (AQS) for therapeutic efficacy were recorded pre and 8 weeks post therapy.Wilcoxon signed-rank and ANOVA tests were used for statistical analysis. Results Partial response (PR), stable disease (SD) and progressive disease (PD) for PSAwere seen in 5 (22.7%), 13 (59.1%) and 4 (18.2%) patients respectively treated with mean 6.88 GBq dose of Lu-177-PSMA. 8/22 (36.4%) patients showed ≥ 30% drop in PSA. Grade 3 haemoglobin toxicity was seen in 5/22 (22.7%) patients. No patient developed grade 4 haemoglobin toxicity. No patients had grade 3 or 4 leukocytopenia or thrombocytopenia. Wilcoxon signed-rank test showed statistical significant (P < 0.05) difference in pre and post treatment ECOG, VAS, and AQS scores. The ANOVA test showed statistically significant difference in mean doses of Lu-177-PSMA used in three PSA response groups while difference was non-significant for other variables. Conclusion We concluded that Lu-177-PSMA therapy has adequate pain palliation in end-stage mCRPC patients with low performance status and it has a potential to become effective therapeutic option in properly selected patients.
-
Manoj Gupta,Partha Sarathi Choudhury,Sudhir Rawal,Harish Chandra Goel,S. Avinash Rao 대한핵의학회 2018 핵의학 분자영상 Vol.52 No.6
Purpose The aim of the study was to compare response evaluation criteria in solid tumours 1.1 (RECIST 1.1), positron emissiontomography response criteria in solid tumours (PERCIST), European organisation for research and treatment of cancer (EORTC),andMDAnderson (MDA) criteria for response assessment by Gallium 68-prostate-specific membrane antigen positron emissiontomography-computed tomography (Ga68-PSMA PET-CT) in metastatic adenocarcinoma prostate cancer (mPCa) patients withbiochemical progression. Methods Eighty-eight mPCa patients with pre and post treatment Ga68-PSMA PET-CTwere included. A ≥ 25% increase and ≥2 ng/ml above the nadir if prostate specific antigen (PSA) drop or ≥ 2 ng/ml above the baseline if PSA does not drop wasconsidered as biochemical progression. RECIST 1.1 and MDA criteria for morphology and PERCIST and EORTC criteria formolecular response were investigated. Percentages of progressive disease (PD), partial response (PR), and stable disease (SD)were calculated. Chi-square test was used for statistical significance. Results Proportion of PD, SD, and PR by RECIST 1.1 and MDA criteria were 44 (50.57%), 39 (44.83%), 4 (4.6%), and 33(39.76%), 48 (57.83%), 2 (2.41%) respectively. Proportion of PD, SD, and PR by PERCIST and EORTC criteria were 71(80.68%), 11 (12.50%), 6 (6.82%), and 74 (84.09%), 8 (9.09%), 6 (6.82%) respectively. Chi-square test showed statisticallysignificant (P < 0.05) higher proportion of progression detected by both molecular criteria as compare to both morphologicalcriteria. Conclusion We concluded that for Ga68-PSMA PET-CT response evaluation, molecular criteria performed better than morphologicalcriteria in mPCa patient with PSA progression.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
